Siddiqui Ali A, Nazario Hector, Mahgoub Amar, Patel Mahir, Cipher Daisha, Spechler Stuart J
Dallas Veteran's Affairs Medical Center, Department of Internal Medicine, Dallas, TX 75216, USA.
Dig Dis Sci. 2009 Jun;54(6):1307-11. doi: 10.1007/s10620-009-0790-8. Epub 2009 Apr 1.
Statins have been found to suppress tumor cell growth and to limit the ability of tumor cells to metastasize in studies involving cell lines and animals. To explore how the long-term use of statins influences the presentation and survival of patients with colorectal cancer (CRC), we conducted a retrospective case-control study of male patients with a new diagnosis of CRC who we categorized as: (1) Statin Users who used statins continuously >/=3 years prior to the diagnosis of CRC and (2) Statin Non-Users who did not use statins. Clinical factors were analyzed by simple Chi-square and multivariate regression analysis to identify independent predictors for advanced CRC. We identified 1,309 male patients with a new diagnosis of CRC (mean age 69 +/- 1.1 (SE) years; 326 Statin Users, 983 Statin Non-Users). Compared to Statin Non-Users, Statin Users had a less advanced tumor stage (2.2 vs. 2.6; P < 0.01), a lower prevalence of metastases (OR = 0.7 [0.4-0.9, 95% CI]; P < 0.01), and a higher frequency of right-sided tumors (OR = 1.6 [1.3-2.1], 95%CI]; P < 0.01). Overall 5-year survival for Statin Users was 37% compared to 33% in Statin Non-Users (OR = 0.7 [0.6-0.9], 95%CI]; P = 0.03). In patients who present to the hospital with CRC, the long-term use of statins is associated with a less advanced tumor stage, a higher prevalence of right-sided tumors, a lower frequency of distant metastases, and a better survival rate.
在涉及细胞系和动物的研究中，已发现他汀类药物可抑制肿瘤细胞生长并限制肿瘤细胞转移的能力。为了探究长期使用他汀类药物如何影响结直肠癌（CRC）患者的病情表现和生存率，我们对新诊断为CRC的男性患者进行了一项回顾性病例对照研究，将这些患者分为：（1）他汀类药物使用者，即在CRC诊断前连续使用他汀类药物≥3年；（2）非他汀类药物使用者，即未使用他汀类药物的患者。通过简单的卡方检验和多变量回归分析对临床因素进行分析，以确定晚期CRC的独立预测因素。我们确定了1309例新诊断为CRC的男性患者（平均年龄69±1.1（SE）岁；326例他汀类药物使用者，983例非他汀类药物使用者）。与非他汀类药物使用者相比，他汀类药物使用者的肿瘤分期较晚（2.2对2.6；P<0.01），转移发生率较低（OR = 0.7 [0.4 - 0.9, 95% CI]；P<0.01），右侧肿瘤的发生率较高（OR = 1.6 [1.3 - 2.1], 95%CI]；P<0.01）。他汀类药物使用者的总体5年生存率为37%，而非他汀类药物使用者为33%（OR = 0.7 [0.6 - 0.9], 95%CI]；P = 0.03）。在因CRC入院的患者中，长期使用他汀类药物与肿瘤分期较晚、右侧肿瘤发生率较高、远处转移频率较低以及生存率较高有关。
